The Department of Health and Human Services (HHS) is pushing a risky experiment that restructures how patients receive care in Medicare Part B. These sweeping changes would cause America’s sickest, most vulnerable patients to suffer a number of negative consequences. The HHS plan would force patients and doctors into a mandatory experiment that would limit patient access to care and treatments, put a middleman between patients and doctors, and impose European-style price fixing on drugs in America, stifling cancer research.
Radio: Listen to AfPA’s Radio Ad
In a storyline reminiscent of holiday favorite “The Grinch,” the Trump administration seems to be using the season of giving to plot the theft of something Americans hold dear – seniors’ Medicare, in this case.
In the News
We are writing on behalf of the Part B Access for Seniors and Physicians (ASP) Coalition, which is committed to advancing life-saving innovation in the U.S. We are greatly concerned about a proposal by the Centers for Medicare & Medicaid Services (CMS) to implement an unprecedented, mandatory experiment affecting Medicare beneficiaries who take Part B-covered drugs. We support efforts to strengthen the United States’ health care system through patient-centered reforms that embrace competition, foster the provider-patient relationship, and value transformation.
Trump Medicare Drug Plan Would Hurt Most Vulnerable Patients
Mercury News, January 2, 2019
PIPC Submits Letter to CMS on Proposed International Pricing Index
PIPC, January 1, 2019
HHS Drug Price Plan Is a Gift to Global ‘Freeloaders’
Real Clear Health, December 27, 2018
Medicare Drug Proposal Will Prevent New Medicines from Coming to Market
The Hill, December 18, 2018
Trump Officials Say Drug Prices Are Inflated. So Are Some of Their Claims on a Solution.
New York Times, December 16, 2018
More Than 300 Groups Seek to Halt CMS’ Plans For Global Drug Pricing Index
AJMC, December 10, 2018
Despite Innovation, Europeans Wait Years for New Cancer Drugs
Reuters, December 3, 2018
Trump’s Misguided Solution to Drug Prices
Galen Institute, December 2, 2018